Gsk Share Discussion Threads

[ygor705] 15/3/2018 09:54

IMO the GSK balance sheet is weak and, in an environment where patent protection on drugs is arguably too short to cope with their upfront development costs, who knows if the goodwill shown as assets in the GSK balance sheet are really worth the value ascribed. Could GSK do a Corporate Bond issue to fund the Pfizer situation? Probably. Would it be medium/long term at a fixed rate? Yes, if GSK has got any sense. Would there also be a rights issue? Yes, I think so. How would the GSK balance sheet look after any acquisition? Even worse than now. Realistically, if the Pfizer situation goes ahead, we should be looking at GSK as a leveraged entity rather than a large corporate. In that situation, the stability of forward revenues and margins plus insulation from interest rate rises will become of critical importance. The danger here is that the Board end up creating a Zombie company.

[al101uk] 15/3/2018 09:01

Bonds pay interest, they have a cost, just like bank finance.

The assumption is that the total cost of debt will overwhelm the companies ability to pay a dividend, whether that is through bonds, banking finance or whatever.

[montyhedge] 15/3/2018 08:54

Yes knock 50p off the share price in one go, if they did win. Investors would think dividend might be under threat, but surely just raise money in the corporate bond market.

[tradermichael] 15/3/2018 07:51

A price that is acceptable to Pfizer would mean that the winner has overpaid ..... ;o)

[montyhedge] 15/3/2018 05:37

I don't know why, I just have a feeling we will win the Pfizer bid.

[jadeticl3] 14/3/2018 16:47

Hi Abdul’s, are you fed up because you did not get a vote? The outcome is called democracy.

[abdullla] 14/3/2018 16:41

Dow tanking 500 points ftse going below 7000 and GSK going below £13 again,take your pick !

[toffeeman] 14/3/2018 15:45

IMM is being pumped by many usernames - each time I see as IMM post I filter the poster.

[romeike] 14/3/2018 14:42

IMM don't even have a sales team and this is the GSK board. Honestly I think IMM must be among the most over hyped stocks on these boards. I wonder how all those punters who bought in over 150p are feeling now it's headed back in the wrong direction.

[top tips] 14/3/2018 14:39

Immupharma (IMM) looks interesting ahead of reporting Phase 3 results for potential blockbuster lupus drug 'Lupuzor' later this month. Data so far indicates it could be far superior to GSK's 'Benlysta'.

Market capitalisation still below £200m at 125p, a potential 100 bagger as the drug could open up the whole of their 'P140' platform to dozens of high value indications.

[abdullla] 13/3/2018 16:45

Imo, the referendum was a big mistake.

[abdullla] 13/3/2018 15:56

Dow still up where as ftse likely to score a century,albeit downwards,a direction less uk market on account of leaving Europe,IMO !

[darias] 13/3/2018 15:38

Discussion on this thread has been about possible acquisition of Pfizer but nobody has commented on this paragraph from the Annual Report published today,

"Dividends represent an allocation of capital and the Board is mindful of the value that many shareholders attach to dividends. Under our framework, any material acquisitions have a lower priority and would have to meet our strict returns criteria."

It is my view that recognises that any deal with Pfizer will have to be eonomically sound and not speculative.

[gallops] 13/3/2018 14:06

Trader Michael
Thanks for the information reply much appreciated.

[abdullla] 13/3/2018 12:09

GSK 15p down now spells Dow mini crash imminent!

[romeike] 13/3/2018 11:57

Another full year of Advair revenue looks likely to support 4 - 7 eps growth for 2018 and yet share price down today sadly. Good news for GSK though, every extra month of ongoing revenues from Advair is a bonus. Need to break resistance at 1350p.

Alphorn filtered.

[ny boy] 12/3/2018 23:23

IMM will be able to buy GSK for petty 💰 soon 🤫

Gradual climb here with a few niggly down days. Steady as she goes Sir

[romeike] 12/3/2018 22:54

About time the shareprice was the other side of 1400p!! - Make that 1700p

[romeike] 12/3/2018 22:54

Please stop discussing IMM on the GSK board. There is an IMM board, go join the dreamers on their board please.

[dr biotech] 12/3/2018 22:27

Hi Alphorn

I have a deep mistrust of UK bios forged through painful experience. Some of their P2 data has promise but there are several red flags too. It’s a 50:50 call imo. The IMM thread is terrible, full of rampers predicting hundred fold gains etc. Sorry for the off topic to everyone else..

[alphorn] 12/3/2018 18:43

DrB - My earlier question concerned IMM.

I am aware of disclosure requirements for full listings. For interest here are the requirements for AIM listings:
"An AIM company must issue notification without delay of any new developments which are not public knowledge which, if made public, would be likely to lead to a significant movement in the price of its AIM securities".

One must therefore assume that there is no output yet from the Stats team.

[tradermichael] 12/3/2018 13:07

gallops: The transfer is a straight transfer. There is no selling and re-purchasing.

I transferred 2 Share accounts and 2 ISA share accounts and the cost was £0. I made sure there was no cash in the account to simplify matters. Once the transfer has happened, any cash from dividends that arrives is gathered by Barclays in a 'sweep' process for 6 months and it is automatically transferred to your AJ Bell account.

1. Open an account with AJ Bell. Then ring them to give them the information that they need to contact Barclays.
2. AJ Bell handle everything from there on, liaising with Barclays.

Because of the mess that Barclays made of the capture of Barclays Stockbrokers accounts, and the lack of resources they had, the process took a long time - for me, from 1 September to December. It should be quicker by now.